Read an article about research by Jean-Pierre Julien on Québec's Chief Scientist website:
It was found that 98% of ALS patients have aggregated TDP-43 protein in their cytoplasm—the substance that surrounds the nuclei of their nerve cells. These aggregates are responsible for the sufferer’s loss of function over time. The researchers relied on a virus to carry tiny synthesized antibodies into the cells to erode the protein. As a result, the cognitive and motor function of the mice improved.
This research could lead to human clinical trials within 2 to 3 years, and offers a hope of stopping the progression of the disease when a patient is diagnosed.
Read the full article here: